The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Promising combination for kappa-restricted RRMM: kappamab, len, dex
Kappamab is a chimeric IgG1 monoclonal antibody specific for kappa myeloma antigen (KMA), a tumor-specific antigen exclusively expressed on the surface of kappa-restricted multiple myeloma (MM) cells. Andrew Spencer, MBBS, FRACP FRCPA, DM, Alfred Health-Monash University, Melbourne, Australia, discusses the rationale and results of a phase IIb, open-label, sequential cohort study comparing kappamab alone to kappamab in combination with lenalidomide and low dose dexamethasone in relapsed/refractory MM. Results indicate that this novel combination may represent a promising new therapeutic option. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
